Posluma (flotufolastat

Posluma is a groundbreaking radioactive diagnostic agent developed for precise and critical positron emission tomography (PET) imaging. It is specifically indicated for detecting prostate-specific membrane antigen (PSMA) positive lesions in men diagnosed with prostate cancer. Posluma plays a pivotal role in two key clinical scenarios:

Candidates for Initial Definitive Therapy: Posluma is a valuable tool for men with suspected metastatic prostate cancer who are in consideration for initial definitive therapy. Its diagnostic power aids in the accurate assessment of the extent of the disease, guiding clinicians in making informed decisions about the most appropriate treatment options.

Suspected Recurrence: For men with elevated serum prostate-specific antigen (PSA) levels, Posluma offers a reliable method for detecting suspected cancer recurrence. By providing precise imaging results, it assists healthcare professionals in identifying and addressing recurrent disease, ultimately influencing patient care and management.

Dosage and Administration 

Recommended Radioactivity: The recommended Posluma dosage is 296 MBq (8 mCi), administered as an intravenous bolus injection. This carefully calibrated radioactivity dosage ensures accurate PET imaging results.

Optimal Imaging Timing: Initiate imaging approximately 60 minutes after Posluma administration. The scanning protocol should begin from the mid-thigh region and proceed to the base of the skull. This comprehensive approach enables a thorough assessment of PSMA-positive lesions.

Comprehensive Guidance: For detailed information on the preparation, handling, administration, imaging procedures, and radiation dosimetry, please refer to the complete prescribing information. This comprehensive resource ensures that healthcare professionals can utilize Posluma to its full potential, guaranteeing the highest standard of care for patients.

• Risk of Image Misinterpretation: While Posluma offers exceptional imaging capabilities, it’s important to note that interpretation errors can occur. Image interpretation may vary depending on the expertise of the imaging readers, especially in patients with suspected prostate cancer recurrence. To mitigate this risk, consider multidisciplinary consultation and histopathological confirmation to ensure accurate diagnosis and appropriate patient management.
• Radiation Risk: Posluma, as a radioactive diagnostic agent, contributes to a patient’s long-term cumulative radiation exposure. It is crucial to follow safe handling procedures to protect both patients and healthcare workers from unintentional radiation exposure. Safety measures should be strictly adhered to during the preparation, administration, and disposal of Posluma

If you are considering the import of Posluma (flotufolastat F 18) to India, please be aware that Poluma  can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

• Required Documentation for Import:
• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.

Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Posluma will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Posluma (flotufolastat F 18)  is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Posluma can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Posluma  (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.